Clinical Trial Update: 5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating 5-fluorouracil in combination with Octreotide Long-Acting Release for neuroendocrine tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Octreotide Long-Acting Release (octreotide long-acting release)

Snippet

Sponsor: University of Turin, Italy | Conditions: Neuroendocrine Tumors | Phase 2 | Status: COMPLETED